Cases & Deals

  • Home
  • Practices
  • Royalty Pharma acquires EMGALITY® royalty from Arteaus Therapeutics for $260 million

Share

Royalty Pharma acquires EMGALITY® royalty from Arteaus Therapeutics for $260 million

April 2019

Client(s) Royalty Pharma

Jones Day advised Royalty Pharma, the industry leader in acquiring pharmaceutical royalties, in its $260 million acquisition of the royalty interest held by Arteaus Therapeutics, LLC on future global net sales of Eli Lilly and Company’s EMGALITY® (galcanezumab), an anti-CGRP antibody for the prevention of migraine.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.